This important study advances a new computational approach to measure and visualize gene expression specificity across different tissues and cell types. The framework is potentially helpful for ...

The collapse of trust in legacy media is well deserved as journalists admit they knew about Eric Swalwell's alleged ...

ALXN1840 has demonstrated a well-characterized and favorable safety profile across Phase 2 and Phase 3 studies (266 patients; median 2.58 years on treatment; max >8 years), with drug-related serious ...

Researchers developed STRIPE, a targeted long-read RNA sequencing tool that identifies disease-causing variants missed by standard tests, improving diagnosis and enabling precision therapies for rare ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

Kailera Therapeutics Inc.’s “obesity-first” approach continues to resonate with investors, with the company pricing an upsized IPO, offering 39 million shares at $16 apiece for gross proceeds of $625 ...

Outdated studies, misunderstood guidance, and the persistence of a safety claim the author says does not hold up.

More data breaches, more AI cases. Data protection authorities are at their limit. The reason is AI, but also cheap ...

The chart below gets to the heart of the matter – the AI tailwind that is powering Google more broadly and Google Cloud ...

LOS ANGELES, April 19, 2026 /PRNewswire/ -- The Breakthrough Prize Foundation today announced the winners of the 2026 Breakthrough Prizes, honoring scientists whose discoveries are significantly ...

The easy money from positioning is fading as macro shorts and CTA demand peak, shifting the market into an earnings-driven ...

More than 2.2 billion people in the world hold anti-Semitic views, warns Sylvan Adams, president of the World Jewish Congress ...